tetano
Editor, Senior Moderator
Gynecol Oncol
. 2021 Dec 7;S0090-8258(21)01629-2.
doi: 10.1016/j.ygyno.2021.12.004. Online ahead of print.
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic
Olivia D Lara[SUP] 1 [/SUP], Maria Smith[SUP] 1 [/SUP], Yuyan Wang[SUP] 2 [/SUP], Roisin E O'Cearbhaill[SUP] 3 [/SUP], Stephanie V Blank[SUP] 4 [/SUP], Valentin Kolev[SUP] 4 [/SUP], Caitlin Carr[SUP] 4 [/SUP], Anne Knisely[SUP] 5 [/SUP], Jennifer McEachron[SUP] 6 [/SUP], Lisa Gabor[SUP] 7 [/SUP], Eloise Chapman-Davis[SUP] 8 [/SUP], Seth Cohen[SUP] 3 [/SUP], Julia Fehniger[SUP] 1 [/SUP], Yi-Chun Lee[SUP] 6 [/SUP], Sara Isani[SUP] 7 [/SUP], Mengling Liu[SUP] 9 [/SUP], Jason D Wright[SUP] 5 [/SUP], Bhavana Pothuri[SUP] 10 [/SUP]
Affiliations
Abstract
Background: Despite significant increase in COVID-19 publications, characterization of COVID-19 infection in patients with gynecologic cancer remains limited. Here we present an update of COVID-19 outcomes among people with gynecologic cancer in New York City (NYC) during the initial surge of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]).
Methods: Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 NYC area hospital systems between March and June 2020. Multivariable logistic regression was utilized to estimate associations between factors and COVID-19 related hospitalization and mortality.
Results: Of 193 patients with gynecologic cancer and COVID-19, the median age at diagnosis was 65.0 years (interquartile range (IQR), 53.0-73.0 years). One hundred six of the 193 patients (54.9%) required hospitalization; among the hospitalized patients, 13 (12.3%) required invasive mechanical ventilation, 39 (36.8%) required ICU admission. Half of the cohort (49.2%) had not received anti-cancer treatment prior to COVID-19 diagnosis. No patients requiring mechanical ventilation survived. Thirty-four of 193 (17.6%) patients died of COVID-19 complications. In multivariable analysis, hospitalization was associated with an age ≥ 65 years (odds ratio [OR] 2.12, 95% confidence interval [CI] 1.11, 4.07), Black race (OR 2.53, CI 1.24, 5.32), performance status ≥2 (OR 3.67, CI 1.25, 13.55) and ≥ 3 comorbidities (OR 2.00, CI 1.05, 3.84). Only former or current history of smoking (OR 2.75, CI 1.21, 6.22) was associated with death due to COVID-19 in multivariable analysis. Administration of cytotoxic chemotherapy within 90 days of COVID-19 diagnosis was not predictive of COVID-19 hospitalization (OR 0.83, CI 0.41, 1.68) or mortality (OR 1.56, CI 0.67, 3.53).
Conclusions: The case fatality rate among patients with gynecologic malignancy with COVID-19 infection was 17.6%. Cancer-directed therapy was not associated with an increased risk of mortality related to COVID-19 infection.
Keywords: Coronavirus disease 2019 (COVID-19); Gynecologic cancer; Outcomes; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2021 Dec 7;S0090-8258(21)01629-2.
doi: 10.1016/j.ygyno.2021.12.004. Online ahead of print.
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic
Olivia D Lara[SUP] 1 [/SUP], Maria Smith[SUP] 1 [/SUP], Yuyan Wang[SUP] 2 [/SUP], Roisin E O'Cearbhaill[SUP] 3 [/SUP], Stephanie V Blank[SUP] 4 [/SUP], Valentin Kolev[SUP] 4 [/SUP], Caitlin Carr[SUP] 4 [/SUP], Anne Knisely[SUP] 5 [/SUP], Jennifer McEachron[SUP] 6 [/SUP], Lisa Gabor[SUP] 7 [/SUP], Eloise Chapman-Davis[SUP] 8 [/SUP], Seth Cohen[SUP] 3 [/SUP], Julia Fehniger[SUP] 1 [/SUP], Yi-Chun Lee[SUP] 6 [/SUP], Sara Isani[SUP] 7 [/SUP], Mengling Liu[SUP] 9 [/SUP], Jason D Wright[SUP] 5 [/SUP], Bhavana Pothuri[SUP] 10 [/SUP]
Affiliations
- PMID: 34922769
- DOI: 10.1016/j.ygyno.2021.12.004
Abstract
Background: Despite significant increase in COVID-19 publications, characterization of COVID-19 infection in patients with gynecologic cancer remains limited. Here we present an update of COVID-19 outcomes among people with gynecologic cancer in New York City (NYC) during the initial surge of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]).
Methods: Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 NYC area hospital systems between March and June 2020. Multivariable logistic regression was utilized to estimate associations between factors and COVID-19 related hospitalization and mortality.
Results: Of 193 patients with gynecologic cancer and COVID-19, the median age at diagnosis was 65.0 years (interquartile range (IQR), 53.0-73.0 years). One hundred six of the 193 patients (54.9%) required hospitalization; among the hospitalized patients, 13 (12.3%) required invasive mechanical ventilation, 39 (36.8%) required ICU admission. Half of the cohort (49.2%) had not received anti-cancer treatment prior to COVID-19 diagnosis. No patients requiring mechanical ventilation survived. Thirty-four of 193 (17.6%) patients died of COVID-19 complications. In multivariable analysis, hospitalization was associated with an age ≥ 65 years (odds ratio [OR] 2.12, 95% confidence interval [CI] 1.11, 4.07), Black race (OR 2.53, CI 1.24, 5.32), performance status ≥2 (OR 3.67, CI 1.25, 13.55) and ≥ 3 comorbidities (OR 2.00, CI 1.05, 3.84). Only former or current history of smoking (OR 2.75, CI 1.21, 6.22) was associated with death due to COVID-19 in multivariable analysis. Administration of cytotoxic chemotherapy within 90 days of COVID-19 diagnosis was not predictive of COVID-19 hospitalization (OR 0.83, CI 0.41, 1.68) or mortality (OR 1.56, CI 0.67, 3.53).
Conclusions: The case fatality rate among patients with gynecologic malignancy with COVID-19 infection was 17.6%. Cancer-directed therapy was not associated with an increased risk of mortality related to COVID-19 infection.
Keywords: Coronavirus disease 2019 (COVID-19); Gynecologic cancer; Outcomes; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).